Psychiatr. pro Praxi, 2007; 8(5): 216-221

Valproate in therapy of bipolar affective disorder

MUDr. Pavel Doubek1, MUDr. Erik Herman1,3,2, doc. MUDr. Jiří Hovorka CSc2,4, doc. MUDr. Ján Praško CSc5,7,6,8
1 Psychiatrická klinika 1. LF UK a VFN Praha
2 Neurologické oddělení, neuropsychiatrické a epileptologické centrum, Nemocnice Na Františku s poliklinikou, Praha
3 Psychiatrická ambulance, Praha
4 Neurochirurgická klinika 1. LF UK, Praha
5 Psychiatrické centrum Praha, 3. LF UK, Praha
6 Centrum neuropsychiatrických studií, Praha
7 Psychiatrická klinika FN a LF UP, Olomouc
8 3. LF UK, Praha

Valproate has been used like mood stabilizer in patients with bipolar affective disorder for long time. Valproate is demonstrable effective in therapy of manic, mixed episodes and in maintaince and prophylactic treatment and in rapid cycling bipolar disorder. Clinical use limitations of valproate are mostly dose depend side effects.

Keywords: bipolar affective disorder, mood stabilizer, valproate, pregnancy, rapid cycling

Published: November 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doubek P, Herman E, Hovorka J, Praško J. Valproate in therapy of bipolar affective disorder. Psychiatr. praxi. 2007;8(5):216-221.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606. Go to original source... Go to PubMed...
    2. Bauer MS, Whybrow PC, Gyulai L, Gonnel J, Yeh HS. Testing definitions of dysphoric mania and hypomania: prevalence, clinical characteristics and inter-episode stability. J Affed Disord 1994; 32: 201-211. Go to original source... Go to PubMed...
    3. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG (Depakote Mania Study Group). Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924. Go to original source...
    4. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (Divalproex Maintenance Study Group). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-489. Go to original source... Go to PubMed...
    5. Brennan MJW, Sandyk R, Borsook D: Use of sodium valproate in the management of affective disorders: basic and clinical aspects, in anticonvulsants in affective disorders. Edited by Emrich HM, Okuma T, Muller AA. Amsterdam, Excerpta Medica,1984: 56-65.
    6. Calabrese JR, Bowden CL, DeVeaugh-Geiss J, Earl NL, Gyulai L, Sachs GS, Montgomery P. Lamotrigine demonstrates long-term mood stabilization in manic patients, in 2001 Annual meeting new research program and abstracts. Washington, DC, American Psychiatric Association, 2001, p 110. Go to original source...
    7. Calabrese JR, Bowden CL, Sachs GS, Ascher JA Monaghan E, Rudd GD (Lamictal 602 Study Group). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88. Go to original source... Go to PubMed...
    8. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147: 431-434. Go to original source... Go to PubMed...
    9. Cohn JB, Collins G, Ashbrook E, Wemicke JF. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-322. Go to original source... Go to PubMed...
    10. Cole AJ, Scott J, Ferrler IN. Eccleston D. Patterns of treatment resistance in bipolar affective disorder. Acta Psychiatr Scand 1993; 88: 121-123. Go to original source... Go to PubMed...
    11. Češková E. Nedoceněný valproát? Čes. a slov. psychiatr. 2001; 97(2): 64-68.
    12. Češková E, Herman E, Doubek P, Praško J. Bipolární afektivní porucha. In: Raboch J, Anders M, Praško J, Hellerová P. Psychiatrie - Doporučené postupy psychiatrické péče. Infopharm 2006, 88-96.
    13. Denicoff KD, Smith Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478. Go to original source... Go to PubMed...
    14. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy? Epilepsia 1993; 34: 827-831. Go to original source... Go to PubMed...
    15. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229-233. Go to original source... Go to PubMed...
    16. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders, V: a double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120. Go to original source... Go to PubMed...
    17. Emrich HM, von Zersem D, Kissling W. On a possible role of GABA in mania: therapeutic efficacy of sodium valproate, in GABA and benzodiazepine receptors. Edited by Costa E, Dicharia G, Gessa GL. New York, Raven Press,1981: 287-296.
    18. Finsterer J, Pelzt G, Hess B: Severe, isolated thrombocytopenia under polytherapy with carbamazepine and valproate. Psychiatry Clin Neurosci 2001; 55: 423-426. Go to original source... Go to PubMed...
    19. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108-111. Go to original source... Go to PubMed...
    20. Genton P, Bauer J, Duncan S, Taylor AE, Balen AH, Eberle A, Pedersen B, Salas-Puig X, Sauer MV: On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42: 295-304. Go to original source... Go to PubMed...
    21. Herman E, Hovorka J. Stabilizátory nálady v těhotenství. Psychiatrie 2001; 5(Suppl. 2): 40-41.
    22. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916. Go to original source... Go to PubMed...
    23. Hirschfeld RM, Allen MH, McElroy JP, Keck PE Jr, Russell JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999; 60: 815-818. Go to original source... Go to PubMed...
    24. Hovorka J. Epilepsie a protizáchvatová léčba u dívek a žen. Čes Slov Neurol Neurochir 63, Suppl. 2000: 1-8.
    25. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla W. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-1388. Go to original source... Go to PubMed...
    26. Krüger S. Bipolar disorder and pregnancy, information for physicians, Desitin., 2000: 3-23.
    27. Lambert PA, Venaud G. Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure 1992; 5: 57-65.
    28. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 34-35. Go to original source... Go to PubMed...
    29. Matička R. Zajímavá, ,neznámá" valproová kyselina. Psychiat. pro Praxi, 2006; 1: 12-14.
    30. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57: 142-146.
    31. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J (European Valproate Mania Study Group). Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol 2000; 20: 195-203. Go to original source... Go to PubMed...
    32. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981; 73: 95-96. Go to original source... Go to PubMed...
    33. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-550. Go to original source... Go to PubMed...
    34. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48:62-68. Go to original source... Go to PubMed...
    35. Sachs GS, Collins MC. A placebo-controlled trial of divalproex sodium in acute bipolar depression. Program and abstracts of the 40th Annual meeting of the American college of neuropsychopharmacology; December 9-13, 2000; Waikoloa, Hawaii, 55-56.
    36. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. A doubleblind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-393.
    37. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: Medication treatment of bipolar disorder. Postgrad Med Special Issue 2000; 1: 1-104.
    38. Shapiro DR, Quitkin FM, Fleiss JL. Response to maintenance therapy in bipolar illness: effect of index episode. Arch Gen Psychiatry 1989; 46: 401-405. Go to original source... Go to PubMed...
    39. Solomon DA, Keitner GI, Miller IW, Shea MT, Keller MB. Course of illness and maintenance treatments for patients with bipolar disorders. J Clin Psychiatry 1995; 56: 5-13.
    40. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264-1266. Go to original source... Go to PubMed...
    41. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 37-42. Go to original source... Go to PubMed...
    42. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011-1017. Go to original source... Go to PubMed...
    43. Tohen M, Chengappa NR et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy Arch Gen Psychiatry. 2002; 59: 62-69. Go to original source... Go to PubMed...
    44. Tohen MF Milton DR, Davis AR. Olanzapine versus divalproex for the treatment of acute mania, in congress poster abstracts. Munich, European college of neuropsychopharmacology, 2000.
    45. Yatham LN. Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: preliminary findings of a randomized double blind study (RIS-INT-46). Int J Neuropsychopharmacol 2000; 3(suppl 1): S142. Go to original source...
    46. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002; 63: 1148-1155. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.